SGLT2 Inhibitor Deal Benchmarks in Metabolic & Obesity

Median Upfront

$751M

Range: $413M - $1.1B

Total Deal Value

$3.6B

Range: $2.3B - $4.8B

Royalty Rate

15% - 27.5%

Tiered up to 31.5%

Dev Milestones

$506M

Range: $342M - $671M

Model Your Deal

Market Analysis

SGLT2 Inhibitor therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 sglt2 inhibitor asset in metabolic & obesity is $751M, with total deal values reaching $3.6B. Development milestones average $506M, while regulatory milestones contribute $618M.

The metabolic & obesity sglt2 inhibitor landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for sglt2 inhibitor metabolic & obesity deals range from 15% to 27.5% at the base tier, with tiered escalation reaching 19%-31.5% on blockbuster sales. Commercial milestones averaging $1.7B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a sglt2 inhibitor metabolic & obesity licensing deal?

Based on our analysis, Phase 2 sglt2 inhibitor licensing deals in metabolic & obesity average $751M in upfront payments, with a range of $413M to $1.1B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for sglt2 inhibitor metabolic & obesity transactions?

The median total deal value for Phase 2 sglt2 inhibitor assets in metabolic & obesity is $3.6B, ranging from $2.3B to $4.8B. This includes development milestones ($506M), regulatory milestones ($618M), and commercial milestones ($1.7B).

What royalty rates are standard for sglt2 inhibitor deals in metabolic & obesity?

Base royalty rates for sglt2 inhibitor metabolic & obesity transactions range from 15% to 27.5%, with tiered escalations reaching 19%-31.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in sglt2 inhibitor metabolic & obesity deals?

SGLT2 Inhibitor metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($506M) make up the largest share, followed by commercial milestones ($1.7B) and regulatory milestones ($618M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating